Literature DB >> 17214349

Angiosarcoma of the heart: case report and review of the literature.

S Batzios1, A Michalopoulos, L Kaklamanis, J Stathopoulos, M Christopoulou, J Koutantos, G P Stathopoulos.   

Abstract

BACKGROUND: Primary angiosarcoma of the heart is an extremely rare malignant disease. PATIENTS AND METHODS: A 32-year-old female with primary angiosarcoma of the heart at an advanced stage with lung and bone metastases is presented. The tumor showed extensive expression of c-erb-B2 and a moderate expression of c-kit. Chemotherapy (cisplatin, epirubicin and ifosfamide) was administered. Herceptin as well as glivec were added to the above combination.
RESULTS: There was a good partial response and the lung deposits almost disappeared. The duration of response was 6 months.
CONCLUSION: This case of angiosarcoma of the heart is presented because of the extreme rarity of this disease, and its responsiveness to chemotherapy in combination with imatinib and herceptin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214349

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Comprehensive treatment of unresectable cardiac angiosarcoma: A case report and review of literature.

Authors:  Chao Wang; Min Shi; Chen Yang; Tao Ma; Jinling Jiang; Ying Liu; Wenqi Xi; Zhenggang Zhu; Jun Zhang
Journal:  Mol Clin Oncol       Date:  2017-08-24

2.  Primary cardiac angiosarcoma: in a patient with a dacron aortic prosthesis.

Authors:  Nathan J Almeida; Priscilla Hoang; Paul Biddle; Amy Arouni; Dennis Esterbrooks
Journal:  Tex Heart Inst J       Date:  2011

Review 3.  Right atrial epithelioid angiosarcoma with multiple pulmonary metastasis confirmed by multimodality imaging-guided pulmonary biopsy: A case report and literature review.

Authors:  Cuiwei Liu; Yanxia Zhao; Zhongyuan Yin; Ting Hu; Jinghua Ren; Jielin Wei; Linka Xie; Jie Xiong; Hongge Wu; Xiaofang Dai; Shihong Fei
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.